NewGene Limited Company Profile

The demand for testing individuals for genetic disorders or cancers that have arisen from acquired genetic variations is growing year on year.  This is being driven by advances in medical genetics where more disorders are being characterised as having causative genetic variations, coupled with the growth in personalised medicine which demands the determination of a patient’s biological characteristics in order to select the most effective therapy regime.

Molecular genetic diagnostics, has been established as a discipline for over three decades, however the underlying technology that is used to deliver tests is still based on a technique developed in 1977 which is both costly and time consuming.
Established through a partnership between the Newcastle Hospitals NHS Foundation Trust and Newcastle University and staffed by renowned experts from each organisation, NewGene is the pioneer in developing, validating and delivering molecular diagnostics using the latest next generation sequencing and genotyping technologies.

Technologies
The latest high throughput DNA sequencing technologies such as the Roche 454 GS-FLX  and Sequenom MALDI-TOF offer significant benefits to molecular diagnostics in terms of a high quality, fast turnaround and lower costs as compared to current established technologies. Whilst these benefits have been realised in the field of genomic research, until recently there has been very little application in molecular diagnostics.

By deploying these technology platforms, NewGene has the capability to handle large volumes of tests ensuring our clients benefit from the economies of scale through competitive pricing and fast turnarounds.
Created in 2008, NewGene has already developed a range of tests for clinically significant inherited disorders and stratified medicine diagnostics for somatic mutations in cancers, delivering services to several UK National Health Service Trusts and overseas healthcare providers.  NewGene’s clients are benefiting from a high quality, rapid turnaround service that can be accessed at low cost.
Integrated service provision

With a background in UK NHS molecular genetics, NewGene’s core team understands that healthcare providers need a reliable service that delivers high quality results on time. In addition NewGene understands that providers can have different needs on the basis of their current service and in house expertise. NewGene routinely works with clients to understand their needs in order to offer an optimal service.

Broad portfolio of tests.
Whilst NewGene has a portfolio of important tests that are established on the new technologies and a pipeline of new tests undergoing development, we recognise that healthcare providers need access to a broad range of tests covering a range of disorders. NewGene has partnered with three UK NHS Regional Genetic Laboratories who can offer tests for over 100 inherited disorders. This means that clients can access a broad range of services through NewGene.

In addition to molecular diagnostics NewGene also offers a fast turnaround and cost effective sequencing and genotyping service for researchers.

NewGene’s expanding portfolio of tests includes the following:-

• Hereditary cancers such as breast cancer, colon cancer and various haemato-oncology disorders.
• Common and rare inherited disorders and syndromes.
• Stratified medicine tests including KRAS, BRAF and EGFR.

Location

International Centre for Life
Newcastle upon Tyne
NE1 4EP
GB

More Information about "NewGene Limited" on BioPortfolio

We have published hundreds of NewGene Limited news stories on BioPortfolio along with dozens of NewGene Limited Clinical Trials and PubMed Articles about NewGene Limited for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of NewGene Limited Companies in our database. You can also find out about relevant NewGene Limited Drugs and Medications on this site too.